COMP <GO>
XENE vs ABBV // FREE CASH FLOW YIELD
Xenon Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: XENE 3
— ABBV 11
▲ FREE CASH FLOW YIELD LEADER: ABBV
LAST: $37.41 (-0.35%) • MKT CAP: $3.64B
fcf-yield
-7.70%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XENE VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XENE | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -7.70% | 3.47% | -11.17 | ABBV | /fcf-yield <GO> |
| Operating Margin | -36.70% | 24.60% | -61.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -34.00% | 6.90% | -40.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 7.70% | 8.60% | -0.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | XENE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | XENE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.3 | 72.8 | -28.50 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.15 | -0.05 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.0x | 113.1x | -84.10 | XENE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.64B | $513.86B | -$510.22B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XENE REV | ABBV REV | XENE GROSS % | ABBV GROSS % | XENE FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | -$279.9M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$184.5M | $17.83B |
| FY 2023 | $0 | $54.32B | — | 44.0% | -$151.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XENE // BETA 1.10
ABBV // BETA 1.15